Vanguard Capital Management
GTBP icon

Vanguard Capital Management’s GT Biopharma GTBP Stock Holding History

Vanguard Capital Management’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$184K Sell
376,399
-75,476
-17% -$30.6K ﹤0.01% 3827
2026
Q1 		$184K Buy
+451,875
New +$247K ﹤0.01% 3811

Other funds holding GTBP

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

Vanguard Capital Management's GTBP Position: Q2 2026 in Review

Vanguard Capital Management reduced its GT Biopharma (GTBP) stake by 17% in Q2 2026, selling an estimated $30.6K and leaving 376,399 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #3827.

Vanguard Capital Management first reported a position in GTBP in Q1 2026 and has held it in 2 quarters since. 57 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Vanguard Capital Management held 376,399 shares of GT Biopharma worth $184K as of Q2 2026.
  • Vanguard Capital Management sold 75,476 GT Biopharma shares in Q2 2026, an estimated $30.6K.
  • GT Biopharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3827 holding.
  • Vanguard Capital Management first reported a position in GT Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 57 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.